FDA OKs Roche’s Tecentriq for first-line lung cancer

The FDA approves Roche (OTCQX:RHHBY) unit Genentech’s Tecentriq (atezolizumab), combined with chemo [Celgene’s Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin], for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK mutations.

https://seekingalpha.com/news/3523561-fda-oks-roches-tecentriq-for-first-line-lung-cancer